Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial (Q88117871)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 June 2014

Language	Label	Description	Also known as
English	Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial	scientific article published on 16 June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

ChEBI release 2020-05-28

phase III clinical trial

1 reference

based on heuristic

inferred from title

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Martin Ridderstråle

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Knut Robert Andersen

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Cordula Zeller

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Gabriel Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Hans J Woerle

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Uli C Broedl

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

EMPA-REG H2H-SU trial investigators

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

16 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

691-700

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycemia: minimizing its impact in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic effects of visceral fat accumulation in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2814%2970120-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(14)70120-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24948511%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q88117871&oldid=1529010465"